Immunocore Holdings plc
IMCR · XNASCIK 1671927fmd_18MC1HKJ92B20HS7V822QPXJE3Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 23 periods
Loading
Latest quarter · Q3 FY2026
Millions- Total revenues
- 102
- Gross profit
- 102
- Operating income
- (14)
- Net income
- (14)
- Free cash flow
- 18
Immunocore Holdings plc (IMCR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Cash from operating activities | -$10.7 million | $26.1 million | -141.1% | 10-K 2026-02-25 · proof |
| Free cash flow | -$15.1 million | $20.9 million | -172.1% | 10-K 2026-02-25 · proof |
| Total assets | $1.1 billion | $1 billion | +5.7% | 10-K 2026-02-25 · proof |
| Total liabilities | $686.2 million | $648.8 million | +5.8% | 10-K 2026-02-25 · proof |
| Cash and cash equivalents | $467.7 million | $455.7 million | +2.6% | 10-K 2026-02-25 · proof |
- What was Immunocore Holdings plc (IMCR)'s cash from operating activities in fiscal 2025?
- Immunocore Holdings plc (IMCR) reported cash from operating activities of -$10.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $26.1 million the year before (-141.1%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was Immunocore Holdings plc (IMCR)'s free cash flow in fiscal 2025?
- Immunocore Holdings plc (IMCR) reported free cash flow of -$15.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $20.9 million the year before (-172.1%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Immunocore Holdings plc (IMCR)'s total assets?
- As of Dec 31, 2025, Immunocore Holdings plc (IMCR) reported total assets of $1.1 billion, against $1 billion a year earlier (+5.7%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Immunocore Holdings plc (IMCR)'s total liabilities?
- As of Dec 31, 2025, Immunocore Holdings plc (IMCR) reported total liabilities of $686.2 million, against $648.8 million a year earlier (+5.8%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Immunocore Holdings plc (IMCR)'s cash and cash equivalents?
- As of Dec 31, 2025, Immunocore Holdings plc (IMCR) reported cash and cash equivalents of $467.7 million, against $455.7 million a year earlier (+2.6%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IMCR&period_type=annual&limit=5"Information only, not investment advice.